|
Variables
|
COX-2 -765 G > C genotypes
|
P*
|
OR (95% CI)†
|
|---|
| |
GG (N, %)
|
GC/CC (N, %)
| | |
|---|
|
Tumor size
| | | | |
|
Less than 2 cm
|
116 (92.1)
|
10 (7.9)
|
0.006
|
1.00 (reference)
|
|
More than 2 cm
|
278 (82.0)
|
61 (18.0)
| |
3.01 (1.47–6.12)
|
|
LN involvement
| | | | |
|
Negative
|
206 (82.1)
|
45 (17.9)
|
0.084
|
1.00 (reference)
|
|
Positive
|
188 (87.9)
|
26 (12.1)
| |
0.63 (0.38–1.07)
|
|
ER
| | | | |
|
Negative
|
140 (86.4)
|
22 (13.6)
|
0.459
|
1.00 (reference)
|
|
Positive
|
254 (83.8)
|
49 (16.2)
| |
1.27 (0.62–2.61)
|
|
PR
| | | | |
|
Negative
|
179 (85.7)
|
30 (14.3)
|
0.620
|
1.00 (reference)
|
|
Positive
|
215 (84.0)
|
41 (16.0)
| |
0.97 (0.49–1.93)
|
|
HER-2
| | | | |
|
Negative
|
262 (84.8)
|
47 (15.2)
|
0.961
|
1.00 (reference)
|
|
Positive
|
132 (84.6)
|
24 (15.4)
| |
1.07 (0.61–1.86)
|
- ER, estrogen receptor; PR, progestin receptor; LN, lymph node; HER-2, human epidermal growth factor receptor 2; CI, confidence interval; OR, odds ratio. The frequency of the variant genotypes of COX-2 -765 G > C polymorphism was significant higher in patients with larger tumor size (>2 cm). *Two-sided χ2 test for the distributions of genotype and allele frequencies. †Adjusted for tumor size, LN involvement, ER, PR and HER-2 status.
